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Polycystic ovary syndrome (PCOS) is one of the most common
female endocrine disorders and a leading cause of female sub-
fertility. The mechanism underlying the pathophysiology of PCOS
remains to be illustrated. Here, we identify two alternative splice
variants (ASVs) of the androgen receptor (AR), insertion and
deletion isoforms, in granulosa cells (GCs) in ∼62% of patients
with PCOS. AR ASVs are strongly associated with remarkable
hyperandrogenism and abnormalities in folliculogenesis, and are
absent from all control subjects without PCOS. Alternative splicing
dramatically alters genome-wide AR recruitment and androgen-
induced expression of genes related to androgen metabolism and
folliculogenesis in human GCs. These findings establish alternative
splicing of AR in GCs as the major pathogenic mechanism for hyper-
androgenism and abnormal folliculogenesis in PCOS.
AR | splicing | hyperandrogenism | folliculogenesis | PCOS
In ovarian follicles, oocytes are surrounded by granulosa cells(GCs), which have crucial endocrine functions. Polycystic ovary
syndrome (PCOS) is a heterogeneous hormonal disorder af-
fecting one in 15 women, and is one of the most common causes
of female infertility (1). Hyperandrogenism and abnormal folli-
cle development, associated with excessively small follicles and
ovulatory dysfunction largely due to GCs dysfunction, charac-
terize the pathogenesis of PCOS. Although the underlying eti-
ology remains unclear, androgens and the androgen receptor
(AR) are considered important on account of their critical roles
in the prevalence of hyperandrogenism and ovarian folliculo-
genesis in this disorder (1–3).
Androgens elicit their effects upon binding to AR, and AR
functions primarily via genomic activities as a nuclear receptor.
In the ovary, AR is predominantly expressed by GCs throughout
most stages of follicular development. Nearly all reproductive
phenotypes observed in global AR knockout mice have been at-
tributed to a lack of AR expression in GCs (3). Haploinsufficiency
for exon 3-deleted mutant AR is associated with a premature
reduction in female fecundity (4), verifying the crucial role of
classical genomic AR activity in normal ovarian function. Clinical
studies have suggested that PCOS might be associated with AR
(CAG)n repeats (5) and rs6152A (6) gene polymorphisms. These
studies promoted interest in investigating the effects of AR in GC
dysfunction in PCOS women. We therefore hypothesized that
abnormally expressed and/or dysfunctional AR plays an important
role in the pathogenesis of PCOS.
Results
Alternative Splice Variants of AR in GCs of PCOS Women.Nested RT-
PCR (Fig. S1A) was used to amplify AR cDNAs from GCs of
Southeastern Han Chinese women undergoing in vitro fertiliza-
tion and embryo transfer. We identified two alternative splice
variants (ASVs) expressed exclusively in PCOS women. One
ASV inserted 69 bp into intron 2 (ivs2) between exons 2 and 3
(insertion isoform, ins) whereas the other skipped exon 3 (de-
letion isoform, del), as demonstrated by agarose gel electro-
phoresis (Fig. 1A) and PCR product sequencing (Fig. 1B). AR
ASVs were not detected in the GCs of controls; whereas ins and
del ARs were coexpressed with wild-type (WT) in 36.8% (WT +
ins) and 25.0% (WT + del) of PCOS patients, respectively. None
of the PCOS patients expressed both ins and del variants (Fig.
1C). Consistent with previous work (7), total AR mRNA levels
were up-regulated in the GCs of PCOS women compared with
controls (Fig. 1D). However, surprisingly, the mRNA levels of
WT AR were reduced (Fig. 1E), whereas those of AR ASVs
were increased (Fig. 1 F and G). Notably, this pattern of ex-
pression was tissue-specific, as peripheral lymphocytes expressed
only WT AR, which was up-regulated in PCOS women (Fig. S2).
The AR protein consists of four functional domains: the
N-terminal transactivation domain, the DNA binding domain
(DBD) containing two zinc fingers translated from exons 2 and 3,
hinge region, and ligand-binding domain (LBD) (Fig. S1B). Se-
quence alterations in both AR ASVs were in-frame and signifi-
cantly altered the sequence of the DBD, especially that of the
second zinc finger (Fig. S1C). Molecular modeling suggests that
these changes dramatically altered the 3D structure of the DBD
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(Fig. 1H). These findings suggest that GC-specific AR ASVs,
which are exclusively expressed in PCOS patients, may alter the
DNA binding properties of AR.
Hyperandrogenism and Abnormal Folliculogenesis in PCOS Women
with AR ASVs. We examined whether AR ASV expression was
associated with clinical features in PCOS women (Table 1).
Hyperandrogenism is the most consistent and prominent di-
agnostic component of PCOS (1). Compared with control and
PCOS women expressing WT alone, those with ins or del, es-
pecially the former, had notably higher serum total testosterone
(TT), serum dehydroepiandrosterone (DHEA) and follicular
fluid free androgen index (FAI). In addition, those with WT and
ins had a longer cycle length as well as higher antral follicle
count, compared with PCOS women with WT alone, whereas
both those with ins and those with del were distinguished from
controls. It is worth pointing out that only ins was associated with
higher follicular fluid levels of anti-Müllerian hormone (AMH),
a growth factor produced solely by small follicles (8). These
results indicate that the GC AR splicing pattern is tightly linked
to hyperandrogenism and abnormalities in folliculogenesis.
The Origin of AR ASVs. To explore the genomic origin of AR ASVs
in the GCs of PCOS women, we sequenced exon 2 and ∼100 bp
of the flanking introns, as well as exon 3 and ∼2 kb of the flanking
introns (Fig. S3A). No mutations were identified in conserved re-
gions; however, one PCOS patient with ins was heterozygous (C/T)
for a single nucleotide in ivs2, and the variant was produced from
only the C allele (Fig. S3B), suggesting ins AR was not randomly
generated. Furthermore, single nucleotide polymorphisms have
been implicated in alternative RNA splicing (9). We examined
the rs6152G/A polymorphism (6) in exon 1 of AR in the GCs of
all patients; however, only the G/G genotype was observed.
Epigenetic modifications, such as differential methylation at
exon-intron boundaries, also have a role in splicing regulation
(10). We analyzed the DNA methylation status of 11 cyto-
sine phosphate guanine (CpG) sites of exon 3 and its flanking
fragments in GCs by bisulfite genomic sequencing PCR (Fig. 2A).
Fig. 1. Identification and genomic origin of ins and del AR
ASVs in the GCs of women with PCOS. (A and B) Repre-
sentative PCR products (A) and corresponding sequencing
results (B) of AR ASVs in patient GCs. Exon boundaries are
indicated with vertical double arrows and the sequence of
the in-frame insertion from ivs2 of ins AR is shown in de-
tail. (C) Percent distribution of AR splicing patterns in
control (n = 120) and PCOS (n = 68) women. (D–G) Relative
mRNA levels of total, WT, ins, and del AR in GCs of PCOS
women compared with controls (*P < 0.05). (H) Optimal
predicted 3D model of the protein structures of AR vari-
ants. α-Helices are purple or red (ivs2), and loops are light
blue. Data are presented as mean ± SEM.
Table 1. AR ASVs are associated with hyperandrogenism in women with PCOS
Clinical parameter
Control PCOS
WT Total WT WT + ins WT + del
n 120 68 26 25 17
Age, year 29.98 ± 0.29 29.09 ± 0.36 29.04 ± 0.56 28.84 ± 0.61 29.53 ± 0.74
BMI, kg/m2 21.84 ± 0.29 22.57 ± 0.43 22.40 ± 0.70 21.84 ± 0.61 23.92 ± 0.96
Cycle length, days 29.37 ± 0.15 53.63 ± 2.98* 51.31 ± 3.53* 66.68 ± 8.21*,† 54.47 ± 4.02*
Antral follicle count 9.28 ± 0.21 18.13 ± 0.49* 17.76 ± 0.64* 21.28 ± 1.06*,† 18.71 ± 1.07*
Day 3 serum LH/FSH 0.70 ± 0.03 1.34 ± 0.09* 1.43 ± 0.16* 1.37 ± 0.16* 1.16 ± 0.17*
Day 3 serum TT, nmol/L 0.72 ± 0.04 1.38 ± 0.08* 1.00 ± 0.08* 1.79 ± 0.13*,† 1.43 ± 0.13*,†
Day 3 serum DHEA, μmol/L 6.62 ± 0.24 8.89 ± 0.51* 6.86 ± 0.34 11.18 ± 1.14*,† 8.85 ± 0.62*
Day 3 serum E2, pmol/L 122.20 ± 5.12 136.15 ± 7.85 120.86 ± 10.49 149.82 ± 15.33 140.21 ± 14.92
r-FSH administered, IU 2,289.9 ± 75.5 1,802.2 ± 63.3* 1,817.0 ± 114.4* 1,901.5 ± 98.3* 1,793.5 ± 82.8
FAI in folliclular fluid 10.76 ± 0.66 20.42 ± 2.12* 13.08 ± 1.62 24.59 ± 3.55*,† 25.56 ± 4.09*,†
E2 in follicular fluid, pmol/L 14,522 ± 446 14,148 ± 654 14,897 ± 719 13,128 ± 1030 14,739 ± 2024
AMH in follicular fluid, μg/L 4.22 ± 0.44 7.65 ± 0.73* 5.82 ± 0.78 9.44 ± 1.30*,† 7.54 ± 1.71
Insulin in follicular fluid, mU/L 34.79 ± 3.23 42.73 ± 3.75 36.68 ± 4.08 43.29 ± 7.15 53.13 ± 8.65
Leptin in follicular fluid, μg/L 14.48 ± 1.16 18.31 ± 1.16* 16.74 ± 1.36 17.74 ± 2.08 22.22 ± 2.71*
AMH, anti-Müllerian hormone; BMI, body mass index; Day 3, third day of spontaneous menstrual cycle; E2, estradiol; FSH, follicle-
stimulating hormone; LH, luteinizing hormone; r-FSH, recombinant FSH. Data are presented as mean ± SEM.
*P < 0.05 versus control WT.
†P < 0.05 versus PCOS WT.
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We observed altered methylation of two CpG sites, located at
intron 2 and exon 3 junction, in PCOS individuals with ins (Fig.
2B), suggesting the possibility that the ins isoform may be the
result of altered DNA methylation.
Reduced Genome-Wide Recruitment Patterns of AR ASVs. We used
adenovirus-mediated expression of hemagglutinin (HA)-tagged
WT, ins, and del ARs to map the genomic recruitment of AR
variants in primary cultures of human GCs. Chromatin immu-
noprecipitation (ChIP) sequencing (ChIP-seq; GEO accession:
GSE58628) showed that genome-wide AR-HA recruitment was
dramatically reduced in GCs overexpressing ins or del (Fig. 3A).
Binding sites of WT AR-HA were strongly enriched for andro-
gen response element (ARE) motifs, whereas those of ins or del
were not (Fig. 3B). Accordingly, ins and del ASVs had distinct
genomic recruitment patterns and enriched motifs (Fig. 3 C and
D and Table S1). Combined with RNA sequencing (RNA-seq)
data, we found that GCs expressing ins or del displayed a reduced
AR-HA binding signal in the regions flanking gene transcription
start sites, especially for highly expressed genes, compared with
WT (Fig. 3E).
To elucidate the molecular basis for the diverse effects of AR
ASVs, we examined their nuclear shuttling dynamics as well as
their ability to bind the AREs of AR target genes. Treatment of
transduced primary GCs with dihydrotestosterone (DHT) in-
duced the nuclear translocation of WT AR, but only partially
for ins or del (Fig. 3F). Next, we overexpressed AR variants
in HEK293FT cells and performed luciferase assays using the
pARE2-TATA-Luc reporter (11). DHT induced remarkable
activation of the reporter in cells transfected with WT, but not in
cells expressing ins or del (Fig. 3G), although coexpression of
WT partially restored reporter activity in cells expressing ins or
del, especially in the latter case (Fig. S4). ChIP assays further
demonstrated reduced DHT-stimulated recruitment of ins and
del AR to the classical ARE in pARE2-TATA-Luc (Fig. 3G).
Thus, attenuated nuclear shuttling and ARE binding result in
distinct genome-wide recruitment patterns of AR ASV.
Altered Gene Expression Related to Follicular Development in GCs
with ASVs. We used RNA-seq to detect and quantitative RT-
PCR (RT-qPCR) to further confirm the transcription effects of
AR ASVs in primary cultures of human GCs. A cluster of genes
were found dysregulated in GCs expressing AR ASVs (Fig. S5 and
Dataset S1). DHT-mediated activation of WT AR significantly
altered the expression of genes related to folliculogenesis including
DHRS13 and DHCR24 (Fig. S6A), steroidogenesis including
PRSS23, PGK1, C1GALT, IGFBP5, IGFBP7, and TMSB10 (Fig.
S6B) and ovulation includingHSPG2, FBN1, SPARC, and PLOD2
(Fig. S6C). DHT-induced gene expression profiles in GCs ex-
pressing ins or del AR differed considerably from those with WT
AR in both variant- and gene-specific manners. Therefore, DHT-
regulated expression of genes related to follicular growth, ste-
roidogenesis and ovulation are significantly altered in GCs ex-
pressing ins or del ASVs.
Effects of AR ASVs in GCs on Hyperandrogenism. We further in-
vestigated how altered GC steroidogenesis contributes to ins and
del AR ASV-associated hyperandrogenism. RT-qPCR showed
that, unlike GCs transduced with WT AR, those transduced
with ins or del did not exhibit DHT-induced up-regulation of
CYP19A1 encoding aromatase, a rate-limiting enzyme for the
conversion of androgens to estrogens (12) (Fig. 4A). Accord-
ingly, GCs expressing ins or del failed to up-regulate the ratios of
E2 to TT and estrone (E1) to androstenedione (A) (Fig. 4B),
which are indicators of aromatase activity (13). In addition,
DHT-induced expression of CYP17A1 encoding 17α-hydroxy-
lase, which catalyzes A biosynthesis (14), was increased only in
GCs transduced with ins (Fig. 4C), and caused elevated A levels
in the conditioned medium (Fig. 4D). To verify the effects of AR
ASVs on androgen metabolism in vivo, we performed similar
assays on GCs and follicular fluids from control and PCOS
women, and obtained consistent results (Fig. 4 E–H). These data
suggest crucial roles for GC AR ASVs in excess androgen ac-
cumulation, subsequently leading to hyperandrogenism.
Next, we tested the ability of AR ASVs to bind potential
AREs in the CYP19A1 promoter. In silico analysis of the geno-
mic DNA 5 kb upstream and downstream of the CYP19A1
transcription start site (TSS) identified four high-scoring putative
AREs (Fig. S7A). ChIP assays in primary GCs demonstrated
DHT-induced recruitment of WT AR-HA to the U1 ARE (Fig.
S7B). The transcriptional activity of WT AR at this ARE was
confirmed in HEK293FT using an U1-TATA-Luc reporter (Fig.
S7C). Then, we used ChIP assays to demonstrate reduced DHT-
stimulated recruitment of ins and del AR ASVs to the CYP19A1
U1 ARE in GCs (Fig. 4I). Our findings strongly suggest that the
suppression of aromatase expression by ins or del AR results
from diminished binding to ARE in the CYP19A1 promoter.
Discussion
Studies conducted in recent decades have mainly focused on the
expression, quantification, and genetic polymorphisms of AR,
and have built a convincing argument that an abnormal AR is
associated with PCOS; however, few studies provided direct ev-
idence for this. We have uniquely documented the roles of AR
ASVs in GCs in the pathogenesis of PCOS, although abnormal
splicing of AR has been considered an important mechanism
accounting for androgen-related diseases in men, including
prostate cancer and androgen insensitivity syndrome (15). The
findings that two AR ASVs including ins and del are expressed
exclusively in the GCs of PCOS women, and not any of women
without PCOS, and that these ASVs are notably associated with
the clinical features of PCOS, suggest that the abnormal AR
splicing is a cause of PCOS in these patients. However, it is worth
further verification in other ethnicities. Our results provide a
basis for pursuing studies on the functional consequences of
these variants in term of GC dysfunction in PCOS. Enhanced
expression of AR ASVs in normal GCs alters genome-wide AR
recruitment patterns and androgen-induced gene expression, via
attenuated nuclear transport and ARE binding, ultimately dis-
rupting androgen metabolism and folliculogenesis. These ob-
servations suggest that abnormal splicing of AR is involved in a
signaling cascade that augments the transcription of related
genes, and subsequently results in hyperandrogenism and ab-
normalities in folliculogenesis in PCOS.
Fig. 2. Altered DNA methylation in PCOS women with ins AR. (A) Bisulfite
genomic sequencing PCR shows the methylation status of individual DNA
strands of exon 3 and its flanking region of AR including 11 CpG sites for
individuals with different AR splicing patterns, with ten clones (shown as
lines) per sample; CpG sites are shown as blank (unmethylated) or filled
(methylated) circles. (B) The above results are summarized as the average
methylation ratio at each CpG site (n = 3, *P < 0.05) with a schematic rep-
resentation of exon 3 and its flanking region of the AR gene.











Our inspection of the clinical characteristics of subjects re-
vealed that both ins and del AR were strongly associated with
higher androgen levels in serum and follicles, particularly ins,
indicating their roles in peripheral and ovarian hyperandrogenism
in PCOS. Of interest, ins was linked to a longer cycle and a greater
number of antral follicles, implying its role in defective ovulation
and unregulated follicular growth in women with PCOS. Consis-
tently, ins was also connected with elevated follicular levels of
AMH, due to GC dysfunction (16) and related to the polycystic
ovary phenotype independently of hyperandrogenism (17). These
results might explain, in part, not only the differences in clinical
appearance between PCOS women and controls, but also the
heterogeneity among PCOS individuals. This finding might facil-
itate the development of clinical diagnostic and classification tests.
With regard to the regulation of AR splicing, the fact that ins
or del AR always coexisted with WT, but not overlapping with
each other, and the GC-specific expression of AR ASVs, to-
gether with the case of a PCOS individual with a heterozygous
intron 2, which demonstrates preferential production in a pa-
rental specific manner, made it worth exploring the rule-based
generation system of AR ASVs. Both ins and del variants were
previously reported in men of a family with receptor-positive
partial androgen insensitivity (18), resulting from a T/A mutation
11 bp upstream of exon 3. Unfortunately, we did not find any
change in cis-acting factors of splicing regulation by DNA se-
quencing. Nevertheless, it is still promising that changes in trans-
acting factors in the splicing machinery could result in AR ASVs
generation in PCOS women, for example epigenetic modifications
(19). As these effects are reversible, this may open up novel
therapeutic approaches to treat PCOS.
What are the potential mechanisms of the distinct transcrip-
tion effects of AR ASVs? As a classical nuclear receptor, AR is
first activated by binding with androgen; it then translocates into
the nucleus and finally binds to tissue-specific AREs to enable
the recruitment of an array of coregulators and the general
transcription machinery, thereby triggering the transcription of
androgen-dependent genes. Firstly, because exons 5–8 are re-
sponsible for the coding hinge and LBD, it is expected that the
ligand binding ability of ins and del is intact, as also evidenced by
previous work (18). Secondly, efficient nuclear shuttling of AR
depends on its nuclear localization signal, which is located in the
junction between the second zinc finger domain of the DBD and
the hinge region (20). The structural changes in the α-helix of the
second zinc finger domain of ins and del are likely to interfere
with the nuclear localization signal, which in turn would result in
impaired nuclear shuttling of ins and del ARs, supported by our
findings using immunofluorescent labeling of HA-tagged AR.
Moreover, it could be possible that AR ASVs change the binding
affinity to nuclear import factors (21) or scaffold proteins (22),
which subsequently retards nuclear translocation. Our related
study to investigate this question is under the way. Thirdly, in AR
DBD, the first zinc finger, encoded by exon 2, defines DNA
binding specificity, whereas the second one, encoded by exon 3,
facilitates receptor dimerization and stabilization of the DNA–
receptor complex (23). Our predictive data revealed that these
two ASVs changed their secondary and spatial structures in the
α-helix of the second zinc finger in DBD, implying at least partial
loss of stability of the DNA–AR complex for both ins and del.
This finding was further confirmed by our ChIP results. In par-
ticular, a dramatic reduction in binding efficiency with CYP19
ARE of ins and del AR led to deficient aromatase expression
and impaired androgen conversion to estrogens, thus contribut-
ing to hyperandrogenism. However, our results showed that
these ASVs could up-regulate the expression of some genes in-
cluding CYP17A1 and IGFBP7, which may be not ARE-medi-
ated, possibly due to additional transcriptional activities. The
GCs used in the present study were collected from patients un-
dergoing IVF (in vitro fertilization). On the other hand, much of
the production of testosterone occurs in the theca cells (24) that
surround the follicle and the GCs. Therefore, it is of significance
to further confirm our findings in unstimulated and nonlutei-
nized GCs and theca cells.
In summary, these findings demonstrate a previously unsus-
pected etiology of PCOS whereby alternative splicing of AR in
GCs can alter the expression of genes related to androgen metab-
olism and folliculogenesis, thereby resulting in hyperandrogenism
and abnormalities in folliculogenesis (Fig. 4J).
Fig. 3. Expression of AR ASVs in primary GCs alters ge-
nome-wide AR recruitment patterns. (A) Heat map of the
ChIP sequencing HA binding signal from −1 kb to +1 kb
surrounding the center of WT AR-HA binding sites in GCs
transduced with AR variants. Each line represents a single
AR-HA binding site and the color scale denotes the AR-HA
signal in reads encompassing each locus per million total
reads. (B) Top-scoring motif in GCs expressing WT AR
(Upper) and its enrichment in GCs expressing AR ASVs
(Lower). (C) ChIP sequencing heat maps of ins (Left) and
del (Right) AR-HA binding sites. (D) Top-ranking binding
motifs enriched in GCs expressing ins (Left) or del (Right)
AR. (E) Combined RNA and ChIP sequencing shows re-
duced AR-HA signal in regions flanking (−2 kb to +2 kb)
gene transcription start sites (TSSs) in GCs expressing
AR variants. The different color lines represent the genes,
the expression levels of which are high (red), moderate
(green), low (blue) and silent (purple). (F) Primary GCs
transduced with the control vector (Vec) or AR-HA variants
were treated with DHT and fluorescently stained with
anti-HA (green) or DAPI (blue, nuclei). (Scale bars, 50 μm.)
(G) DHT-induced transcriptional activation of (left, lucifer-
ase assay), and recruitment of AR-HA variants to (right, ChIP
assay), a classical ARE-luciferase reporter in HEK293FT cells
(n = 4, *P < 0.05). White columns: DHT (-); colored columns:
DHT (+). Data are presented as mean ± SEM.
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Materials and Methods
Patient Selection and Sample Collection. PCOS patients, diagnosed according
to the Rotterdam Consensus (European Society for Human Reproduction
and Embryology/American Society for Reproductive Medicine criteria) and
womenwith tubal factor infertility (serving as controls) seeking IVF treatment
at the Women’s Hospital of the School of Medicine of Zhejiang University
were recruited and gave their written informed consent. The ovarian mor-
phology assessed by ultrasound in the controls was normal for every patient.
The long agonist protocol for controlled ovarian hyperstimulation (COH)
and the collection of follicular fluids and GCs, obtained by follicular aspi-
ration from women undergoing oocyte retrieval for IVF, were performed as
described (25). All patient studies were approved by the Ethics Committee of
the Women’s Hospital, School of Medicine, Zhejiang University.
Primary Culture. Human GCs of control subjects were isolated and cultured as
previously described (25).
Reverse Transcription Nested PCR and Quantitative Real-Time PCR. Total RNA
was isolated using the RNAiso Reagent and cDNA was prepared using the
PrimeScript RT kit. Nested PCR was carried out using the Premix Ex Taq Hot
Start Version, and quantitative real-time PCR was performed with the Premix
Ex Taq (Probe qPCR) system or the SYBR Premix Ex Taq (Tli RNaseH Plus)
system (TAKARA). Glyceraldehyde-3-phosphate dehydrogenase served as the
internal control.
Protein Structure Prediction. The 3D structure of WT, ins, and del AR was
predicted using I-TASSER computer modeling and visualized using VMD1.9.1.
Measurement of Hormones. The levels of day 3 serum hormones were mea-
sured in the clinical laboratory of Women’s Hospital, School of Medicine,
Zhejiang University by chemiluminescence immunoassay (CLIA). TT levels in
serum were measured after exaction (26) using CLIA (Roche). TT, SHBG, E2
levels in follicular fluids were detected as described (25). FAI was calculated
as TT divided by SHBG × 100 (27). Follicular levels of AMH, insulin, and leptin
were measured by ELISA (R&D).
Cell Transfections and Luciferase Assay. Expression vectors for WT, ins, and del
AR, as well as the pARE2-TATA-Luc (28) and U1-TATA-Luc reporter vectors,
were purchased from GeneCopoeia. Constructs were transfected into
HEK293FT cells using the FuGENE HD transfection reagent (Roche). The lu-
ciferase assay was performed using the Luciferase Assay System (Promega).
Adenovirus Infections. Adenoviral expression systems for HA-tagged WT, ins,
and del AR were purchased from SinoGenoMax, Beijing, China. Transduction
of primary cultured human GCs was performed as described (29).
Immunofluorescence. GCs were immunostained with primary antibodies
against HA (Cell Signaling, catalog #2367) using a standard protocol as de-
scribed (25). Cell nuclei were stained with DAPI and staining was visualized
using a laser-scanning confocal microscope fitted with a 10 × 60 objective
lens (Zeiss).
ARE Screening and Chromatin Immunoprecipitation (ChIP) Analysis. Putative
androgen-response elements (ARE) were identified in the CYP19A1 promoter
sequence using the Regulatory Sequence Analysis Tools (RSAT) program (30).
ChIP was performed as described (31) with primary antibodies against HA
Fig. 4. Roles of AR ASVs in GCs in ovarian hyper-
androgenism. (A–D) In vitro effects of overexpressed AR
variants in primary GC as indicated by CYP19A1 (aroma-
tase) mRNA levels (A), estrogen to androgen ratios (B),
CYP17A1 (17α-hydroxylase) mRNA levels (C), and A pro-
duction (D) (n = 6, *P < 0.05). (E–H) In vivo effects of AR
variants on androgen metabolism in control and PCOS
women as indicated by GC CYP19A1 expression (E), fol-
licular fluid estrogen to androgen ratios (F), CYP17A1
expression (G), and follicular fluid A levels (H) (n = 28, 12,
17 and 5 in the control WT, PCOS WT, ins, and del groups,
respectively, *P < 0.05). (I) ChIP assay measuring the re-
cruitment of HA-tagged AR to the U1 ARE site in the
CYP19A1 promoter of primary GCs transduced with AR
variants (n = 9, *P < 0.05). (J) Schematic diagram of the
roles of AR ASVs in GCs in the context of hyperandrogenism
and abnormal follicular development. Green (upward) and
red (downward) triangles denote increases and decreases,
respectively. Data are presented as mean ± SEM.











(Abcam, ab9110). Precipitated DNA was amplified by quantitative real-
time PCR.
RNA-seq. Total RNA was extracted using the RNeasy Mini kit according to the
manufacturer’s protocol (Qiagen). Total RNA was used to generate an Illu-
mina RNA-seq library using the mRNA-seq 8 Sample Preparation kit (Illu-
mina). RNA-seq libraries were sequenced and quantified on a HiSeq 2000
apparatus (Illumina). Raw reads were mapped to the hg19 using the TopHat
version (v2.0.13) (32). We assigned RPKM (Reads per kilobase per million) as
an expression value for each gene using Cufflinks version 2.2.1 (33). Heat
maps were generated by using the Cluster 3.0 and Treeview. The Cuffdiff
was used to identify differentially expressed genes (34) in GCs from DHT (+)
versus the DHT (−). Functional enrichment analysis was performed on the
differential expressed genes using DAVID Bioinformatics Resources 6.7 (david.
abcc.ncifcrf.gov) (35).
ChIP-Seq and Data Processing. Library preparation and Illumina sequencingwere
performed according to the manufacturer’s protocol. AR–HA samples were se-
quenced on a HiSeq 2000 apparatus (Illumina). Sequenced reads were mapped
to the human genome (hg19) by SOAP2 (36) and peaks were identified using
MACS (37). WT, ins, and del AR heatmaps were ordered by strength of HA
binding signals in cells overexpressing HA-tagged WT AR. Enriched motifs from
TRANSFAC (38) were found among ChIP regions by the SeqPos motif tool of
CISTROME (39) through scanning the sequences of the AR–HA-binding regions
using position weight matrices (PWMs) for known transcription factors from the
TRANSAC databases, with the entire human genome as a background model.
The occurrence of known motifs within the strongest 2,000 AR–HA-binding sites
was calculated with MAST (40). Enrichment of AR–HA signals within gene bodies
was divided into four categories according to the level of gene expression (high,
moderate, low, and silent). Two-kilobase regions upstream and downstream of
the gene TSS were divided into 20 intervals, and the tag density of each interval
was shown in tag density plots.
Statistics. Data are presented as mean ± SEM (n is the number of tissue
preparations, cells or separate experiments, as indicated in the figure leg-
ends). Statistical analysis was performed by unpaired two-tailed Student’s t
tests, one-way analysis of variance with post hoc tests, or their equivalent
nonparametric tests (version 16.0; SPSS). P < 0.05 was considered statistically
significant.
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